BPC-157: A Researcher’s Compound Profile
BPC-157 is a synthetic pentadecapeptide that has become a subject of growing interest in preclinical research. Derived from a partial sequence of human gastric juice protein, it is studied for its biochemical properties and molecular behaviour in controlled laboratory settings.
Background and discovery
BPC-157 — formally designated Body Protection Compound-157 — is a synthetic pentadecapeptide comprising 15 amino acid residues. Its sequence is derived from a naturally occurring protein found in human gastric juice. The compound itself, however, does not occur endogenously in this isolated form; it is a stable, synthetic fragment created for use as a research tool.
Initial characterisation of this compound emerged from academic research laboratories investigating gastric-derived proteins and their associated molecular fragments. As a synthetic derivative, BPC-157 has been the subject of numerous peer-reviewed in vitro and in vivo preclinical studies examining its biochemical profile, stability characteristics, and molecular interactions. For researchers new to synthetic peptides, our Research Journal primer on peptide fundamentals provides useful background on how synthetic peptides are produced and characterised.
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
15-residue sequence. Molecular stability is attributed in part to the proline-rich central region, which confers resistance to proteolytic degradation under standard laboratory conditions.
Structural characteristics
As a pentadecapeptide, BPC-157 is defined by its 15-residue primary sequence. The presence of multiple proline residues within the chain is a structurally significant feature. Proline’s cyclic pyrrolidine side chain introduces conformational rigidity into peptide chains, restricting backbone flexibility and contributing to resistance against enzymatic degradation — a property frequently noted in the preclinical literature.
The compound exhibits stability in aqueous solution at physiological pH ranges, which has made it a practical subject for in vitro research. Unlike many peptides that require extensive protective modification to withstand experimental conditions, BPC-157’s native sequence demonstrates a degree of inherent resilience that researchers have found useful in designing experimental protocols.
Synthesis and production
Research-grade BPC-157 is produced via solid-phase peptide synthesis (SPPS), the same Merrifield-derived methodology used for the majority of synthetic peptides in laboratory supply. The Fmoc (fluorenylmethyloxycarbonyl) protection strategy is the standard approach for sequences of this length and composition, allowing precise residue-by-residue chain assembly on a solid resin support.
Following chain assembly, cleavage from the resin and global deprotection yields the crude peptide, which is then subjected to preparative high-performance liquid chromatography (HPLC) to achieve the purity levels required for research applications. At Paradiso Peptides, each batch of BPC-157 is verified by independent third-party analysis using both HPLC and mass spectrometry, with full Certificate of Analysis documentation available for every vial shipped.
Lyophilisation and storage
Paradiso Peptides supplies BPC-157 in lyophilised (freeze-dried) form. Lyophilisation removes water through sublimation under vacuum, converting the peptide from aqueous solution into a stable powder matrix. This process significantly extends shelf stability by removing the primary vector for hydrolytic degradation.
Lyophilised BPC-157 should be stored at -20°C in a desiccated environment, away from repeated freeze-thaw cycling. Prior to use in laboratory protocols, reconstitution with a suitable solvent — typically sterile water or a buffered aqueous solution — is standard practice. Researchers should prepare working solutions immediately prior to use and avoid prolonged storage of reconstituted material.
Research context and literature
BPC-157 has accumulated a substantial body of preclinical literature since its initial characterisation. The majority of published studies are in vitro cell culture experiments or rodent model investigations conducted under controlled laboratory conditions. It is important to note that preclinical research findings do not constitute clinical evidence, and no approved therapeutic applications exist for this compound.
A 2025 systematic review published via PubMed Central surveyed 36 preclinical studies on BPC-157 published between 1993 and 2024, examining the compound’s documented behaviour across a range of controlled laboratory models. Separately, a peer-reviewed study in PMC investigated BPC-157’s interactions with growth hormone receptor expression in isolated tendon fibroblast cell cultures, finding dose- and time-dependent upregulation at both mRNA and protein levels — observations confined strictly to in vitro conditions. A further 2025 literature and patent review (MDPI Pharmaceuticals) summarised the compound’s documented molecular interactions across preclinical models, noting the absence of approved clinical applications and the need for comprehensive human studies before any therapeutic conclusions can be drawn.
As with all research peptides, results observed in preclinical models are not necessarily predictive of outcomes in other biological systems, and no extrapolation to human physiology should be inferred from in vitro or animal model data.
Considerations for researchers
Researchers selecting BPC-157 for laboratory investigation should consider several practical factors. Solubility is typically good in aqueous buffers at physiological pH, though concentration-dependent aggregation has been noted at higher molarities in some protocols. Pilot solubility testing at the intended working concentration is recommended before committing to large-scale experimental runs.
As a peptide of gastric origin, BPC-157’s behaviour may be influenced by pH conditions in experimental media. Researchers working with cell culture systems should account for the buffering capacity of their chosen media when designing dose-response experiments. Stock solution preparation, aliquoting strategy, and freeze-thaw management are all variables that can materially affect experimental reproducibility.
Sourcing BPC-157 for research
The quality of results in peptide research is fundamentally linked to the quality of the compound used. BPC-157, like all research peptides, must meet rigorous analytical standards to serve as a reliable experimental tool. Key parameters researchers should verify when sourcing include purity by HPLC, sequence confirmation by mass spectrometry, and batch-specific Certificate of Analysis documentation.
Paradiso Peptides produces BPC-157 under strict quality protocols, with every batch independently tested and documented. You can review our full quality and testing standards here. Our supply is intended exclusively for qualified laboratory researchers — if you have questions about suitability for your research application, our support team is available to assist. For answers to common sourcing and compliance questions, visit our FAQ page.